Immunohistochemical Evaluation of Androgen Receptor, HER-2/neu, and p53 in Benign Pleomorphic Adenomas

被引:0
|
作者
DeRoche, Tom C. [1 ]
Hoschar, Aaron P. [1 ]
Hunt, Jennifer L. [1 ]
机构
[1] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Immunohistochemical stains for androgen receptor (AR), HER-2/neu, and p53 are used as diagnostic markers associated with malignancy in several histologic types of salivary gland tumors. These markers may be useful in differentiating pleomorphic adenoma with cytologic atypia from intracapsular carcinoma ex pleomorphic adenoma (CXPA), as these tumors are often difficult to distinguish on the basis of morphology alone. Objective.-To determine whether AR, HER-2/neu, and p53 expression can be seen in entirely benign pleomorphic adenomas. Design.-Androgen receptor, HER-2/neu, and p53 immunoreactivity was assessed in 41 histologically and clinically benign pleomorphic adenomas. Results.-A total of 3 of 41 pleomorphic adenomas exhibited multifocal areas with moderate staining for HER-2/neu and AR. The positive staining was mainly confined to the epithelial component, where the ductal epithelium showed no cytologic atypia. Immunoreactivity for p53 was observed in the epithelial component of 5 of 41 cases, none of which stained for HER-2/neu and AR. Mean mitotic rate and Ki-67 index were 1 per 10 high-powered fields and 2.7% in HER-2/neu- and AR-positive cases and 1 per 10 high-powered fields and 2.2% in p53-positive cases. Conclusions.-HER-2/neu, AR, and p53 are expressed in a subset of histologically and clinically benign pleomorphic adenomas. These markers cannot be used to reliably predict early carcinomatous transformation in pleomorphic adenoma.
引用
收藏
页码:1907 / 1911
页数:5
相关论文
共 50 条
  • [1] Immunohistochemical evaluation of androgen receptor, Her-2neu, and p53 in benign pleomorphic adenomas
    DeRoche, T.
    Hoschar, A. P.
    Hunt, J. L.
    LABORATORY INVESTIGATION, 2007, 87 : 221A - 222A
  • [2] Immunohistochernical evaluation of androgen receptor, Her-2neu, and p53 in benign pleomorphic adenomas
    DeRoche, T.
    Hoschar, A. P.
    Hunt, J. L.
    MODERN PATHOLOGY, 2007, 20 : 221A - 222A
  • [3] IMMUNOHISTOCHEMICAL ANALYSIS OF P53 AND HER-2/NEU PROTEINS IN HUMAN TUMORS
    CHANG, K
    DING, I
    KERN, FG
    WILLINGHAM, MC
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1991, 39 (09) : 1281 - 1287
  • [4] p53 and Her-2/neu in juvenile angiofibromas
    Schick, B
    Veldung, B
    Wemmert, S
    Jung, V
    Montenarh, M
    Meese, E
    Urbschat, S
    ONCOLOGY REPORTS, 2005, 13 (03) : 453 - 457
  • [5] HER-2/neu and p53 in osteosarcoma: An immunohistochemical and fluorescence in situ hybridization analysis
    Tsai, JY
    Aviv, H
    Benevenia, J
    Chang, VT
    Patterson, F
    Aisner, S
    Hameed, M
    CANCER INVESTIGATION, 2004, 22 (01) : 16 - 24
  • [6] The epidemiology of Her-2/neu and P53 in breast cancer
    Bernstein, JL
    López-Carrillo, L
    Wang, L
    SALUD PUBLICA DE MEXICO, 1999, 41 : S114 - S123
  • [7] p53 and HER-2/neu overexpression in ovarian borderline tumors
    Eltabbakh, GH
    Belinson, JL
    Kennedy, AW
    Biscotti, CV
    Casey, G
    Tubbs, RR
    GYNECOLOGIC ONCOLOGY, 1997, 65 (02) : 218 - 224
  • [8] P53, Her-2/neu and VEGF determined immunohisochemically in chondrosarcoma
    Kharatishvily, TK
    Stepanova, E
    Mousaev, ER
    Aliev, MD
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 274 - 274
  • [9] Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice
    Nanni, P
    Nicoletti, G
    De Giovanni, C
    Croci, S
    Astolfi, A
    Landuzzi, L
    Di Carlo, E
    Iezzi, M
    Musiani, P
    Lollini, PL
    CANCER RESEARCH, 2003, 63 (11) : 2728 - 2732
  • [10] Predictive value of p53 and Her-2/neu proteins in patients with breast cancer
    不详
    BREAST, 2005, 14 : S21 - S21